Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy

Jessica Ann Chacon1,2, Shari Pilon-Thomas3, Amod A Sarnaik3, and Laszlo G Radvanyi1,2,*

1Department of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA; 2The Immunology Program of the University of Texas Health Science Center; Graduate School of Biomedical Sciences; The University of Texas MD Anderson Cancer Center; Houston, TX USA; 3Immunology Program; H Lee Moffitt Cancer Center and Research Institute; Tampa, FL USA

Keywords: 4–1BB, adoptive cell therapy, CD137, co-stimulation, melanoma, tumor-infiltrating lymphocytes

The adoptive reinfusion of autologous tumor-infiltrating lymphocytes (TILs) expanded (and optionally activated) ex vivo is emerging as an effective salvage approach for metastatic melanoma patients who have progressed in spite of several therapeutic regimens, including approaches based on the blockade of cytotoxic T lymphocyte-associated protein 4 (CTLA-4)- and programmed death 1 (PD1)-regulated immunological checkpoints.1,2 In this setting, TILs are first grown from tumor fragments in the presence of high interleukin-2 (IL-2) concentrations, followed by a rapid expansion protocol (REP) in which T cells are induced to rapidly proliferate by means of a transiently lymphodepleting chemotherapeutic regimen facilitates TIL persistence by stimulating their homeostatic expansion and has led to considerably improved response rates.2 However, the expansion of TILs, notably CD8+ cells, with optimal effector properties and persisting as a pool of memory cells that turn over and differentiate into effectors to maintain durable antitumor responses remains elusive.3

Co-stimulation through members of the tumor necrosis factor receptor (TNFR) family appears to be critical for the generation of T cells with optimal effector-memory properties for adoptive cell therapy. Our work suggests that continuous 4–1BB/CD137 co-stimulation is required for the expansion of T cells with an optimal therapeutic profile and that the administration of 4–1BB agonists upon adoptive cell transfer further improves antitumor T-cell functions.

Abbreviations: ACT, adoptive cell therapy; AICD, activation-induced cell death; PBMC, peripheral blood mononuclear cell; REP, rapid expansion protocol; TIL, tumor-infiltrating lymphocyte

Co-stimulation signals are required for the productive activation, expansion and differentiation of naïve T cells, notably as they prevent anergy and activation-induced cell death (AICD). Thus, CD28, an immunoglobulin protein family member, and CD27, a member of the TNFR superfamily, deliver crucial co-stimulatory signals during the initial phases of T-cell activation.4 Conversely, TNFR-like receptors such as 4–1BB/CD137 and OX40/CD134 play a prominent role as co-stimulatory molecules especially at the effector-memory stage.5 Of note, 4–1BB has also been reported to stimulate the expression of CD28, thus increasing the susceptibility of T cells to co-stimulation.6

For the most part, TILs consist of differentiated effector-memory cells that have lost CD27 and CD28 expression, thus (1) being susceptible to AICD and (2) being hyporesponsive to TCR stimulation.7 At least in part, this reflects the upregulation of PD1 and other co-inhibitory receptors on the cell surface. We have found that CD8+ TILs also express high levels of 4–1BB and OX40, though to a lesser extent) upon TCR activation.8,9

In particular, a significant frequency of freshly isolated CD8+ TILs express 4–1BB as well as PD1. As the simultaneous expression of these markers is indicative of recent antigenic stimulation, CD8+ 4–1BB+PD1+ TILs may be enriched of tumor-specific lymphocytes. During initial IL-2-based ex vivo expansion phase, 4–1BB is down-regulated, but can be rapidly upregulated again upon TCR stimulation.9 We found that CD8+ TILs subjected to the REP...
However, current protocols for TIL expansion are not designed to facilitate the specific expansion of CD8+ cells, and frequently their CD4+ counterparts predominate. We found that during the first few days of the REP, CD8+ T cells express high levels of 4–1BB, prompting us to test whether 4–1BB co-stimulation would affect the expansion or overall quality of TILs, specifically within the CD8+ subset, for ACT. Importantly, the use of a fully human agonistic anti-4–1BB antibody during the REP dramatically increased the yield of CD8+ T cells. These cells maintained memory markers such as CD28 and eomesodermin while expressing increased levels of anti-apoptotic molecules, perforin and granzyme B.8 4–1BB-co-stimulated TILs also exhibited an improved proliferative response to melanoma-associated antigens.8 Of note, an alternative way of delivering 4–1BB co-stimulatory signals to expanding TILs prompted us to investigate the effects of 4–1BB co-stimulation on the differentiation and function of melanoma-derived CD8+ TILs in the course of ex vivo expansion. Initially, we were interested in post-REP TILs in which the expression of both CD27 and CD28 is lost (Fig. 1). We found that post-REP TILs are highly sensitive to AICD even in the presence of nominal levels of TCR stimulation.9 This might represent a dilemma in vivo, when TILs get in contact with their cognate antigen, and may explain why many T-cell clones are deleted soon upon adoptive transfer (Fig. 1). However, 4–1BB was rapidly upregulated by TILs subjected to TCR stimulation, and the activation of 4–1BB with either its natural ligand (4–1BB-L) or agonistic anti-4–1BB antibodies not only prevented AICD, but also resulted in continued cell expansion and improved memory and effector phenotype.9 These results suggest that the provision of exogenous 4–1BB co-stimulation in vivo may be useful to improve the persistence and antitumor activity of adoptively transferred (and perhaps endogenous) T cells. Clinical trials based on 4–1BB-activating agents would be useful to test this hypothesis. Of note, we found that the 4–1BB co-stimulatory pathway can be triggered with relatively low levels of agonists. Thus, 4–1BB-activating agents may be able to induce therapeutic antitumor responses along with limited (in incidence and severity) side effects.

We have recently reported that the total number of TILs, as well as the total number of infused CD8+ cells, correlates with clinical responses in melanoma patients undergoing adoptive cell therapy (ACT).1 However, current protocols for TIL expansion are not designed to facilitate the specific expansion of CD8+ cells, and frequently their CD4+ counterparts predominate. We found that during the first few days of the REP, CD8+ T cells express high levels of 4–1BB, prompting us to test whether 4–1BB co-stimulation would affect the expansion or overall quality of TILs, specifically within the CD8+ subset, for ACT. Importantly, the use of a fully human agonistic anti-4–1BB antibody during the REP dramatically increased the yield of CD8+ T cells. These cells maintained memory markers such as CD28 and eomesodermin while expressing increased levels of anti-apoptotic molecules, perforin and granzyme B.8 4–1BB-co-stimulated TILs also exhibited an improved proliferative response to melanoma-associated antigens.8 Of note, an alternative way of delivering 4–1BB co-stimulatory signals to expanding
TILs is provided by so-called “artificial antigen-presenting cells,” for instance, myelogenous leukemia K562 cells engineered to overexpress 4–1BB-L or another ligand for co-stimulatory receptors.10

Another shortcoming of current ACT protocols is an inefficient expansion of sufficient numbers of CD8+ T cells from initial tumor biopsies, the time that is required to initially grow out enough TILs for larger-scale rapid expansion or “REP” (Fig. 1), and the heterogeneous nature of expanded cells, especially in terms of antitumor reactivity. Our data showing that CD8+ TILs freshly isolated from melanoma lesions express 4–1BB have also prompted us to investigate the role of 4–1BB ligation during the “pre-REP” TIL expansion phase (Fig. 1).

Preliminary data suggest that 4–1BB co-stimulation accelerates the outgrowth of CD8+ TILs enriched in tumor-specific cells (Pilon-Thomas and Chacon, unpublished observations).

In summary, our results suggest that provision of continuous 4–1BB co-stimulation will generate optimal T cells for ACT and to improve their biological activity upon reinfusion.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References
1. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012; 18:6758-70; PMID:23032743; http://dx.doi.org/10.1158/1078-0432.CCR-12-1177
2. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
3. Dudley ME, Wunderlich JR, Sheltone TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26:332-42; PMID:12843795; http://dx.doi.org/10.1097/00002371-200307000-00005
4. Bertram EM, Dawicki W, Sedgmen B, Bramson JL, Lynch DH, Watts TH. A switch in costimulation from CD28 to 4–1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol 2004; 172:981-8; PMID:14707071
5. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23:23-68; PMID:15771565; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115839
6. Habib-Agahi M, Jaberipour M, Searle PF. 4–1BBL costimulation retrieves CD28 expression in activated T cells. Cell Immunol 2009; 256:59-66; PMID:19217084; http://dx.doi.org/10.1016/j.cellimm.2009.01.003
7. Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L. MART-1 specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capacity following antigenic restimulation in vitro. J Immunol 2010; 184:452-65; PMID:19949105; http://dx.doi.org/10.4049/jimmunol.0901101
8. Chacon JA, Wu RC, Sukhamalchandra P, Mollodrem JJ, Sarnaik A, Pilon-Thomas S, et al. Co-stimulation through 4–1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 2013; 8:e60031; PMID:23560068; http://dx.doi.org/10.1371/journal.pone.0060031
9. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, et al. Costimulation through the CD137/4–1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011; 34:236-50; PMID:21389874; http://dx.doi.org/10.1097/CJI.0b013e3182097ec
10. Sluijter BJ, van den Hout MF, Stam AG, Lougheed SM, Suhoski MM, van den Eertwegh AJ, et al. 4–1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. Clin Immunol 2010; 137:221-33; PMID:20708974; http://dx.doi.org/10.1016/j.clim.2010.07.009